← Leaderboards
Robyn J Barst
Columbia University Health Sciences
$2,557,256
Attributed
$2,557,256
Total exposure
8
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,557,256 · 8
By mechanism
M01$2,557,256 · 8
Top collaborators
No co-investigators on record.
Most similar at Columbia University Health Sciences
Same institution · by research overlap
- Stuart D Katz$171,255,562
- Daichi Shimbo$28,917,433
- Steven M Kawut$28,347,465
- Muredach P Reilly$136,077,018
- Neil W. Schluger$4,200,595
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectPulmonary HypertensionDrug Screening /EvaluationHuman Therapy EvaluationCardiovascular Disorder ChemotherapyProstacyclinsVasomotionDrug Adverse EffectDrug Administration RoutesExerciseHemodynamicsCombination ChemotherapyCardiovascular Disorder DiagnosisPlacebosRespiratory Disorder ChemotherapyRespiratory FunctionVasodilationVasodilatorsLongitudinal Human StudyNitric OxideCardiovascular AgentsPulmonary CirculationAntihypertensive Agents
Grant awards (32)
LONG TERM PROSTACYCLIN IN PULMONARY HYPERTENSION$192,910
M01 · FY2002 · RR
UT 15 IN PRIMARY PULMONARY HYPERTENSION PIVOTAL 12 WEEK STUDY$192,910
M01 · FY2002 · RR
SUBCUTANEOUS UT 15 IN PATIENTS W/ PRIMARY PULMONARY HYPERTENSION PRE$192,910
M01 · FY2002 · RR
SAFETY &EFFICACY OF TERBOGREL IN PATIENTS W/ PRIMARY PULMONARY HYPER$192,910
M01 · FY2002 · RR
NITRIC OXIDE IN PATIENTS WITH PULMONARY HYPERTENSION$192,910
M01 · FY2002 · RR
PROSTACYCLIN AND SUBSEQUENT THERAPY IN PULMONARY HYPERTENSION$192,910
M01 · FY2002 · RR
PROSTACYCLIN AND SUBSEQUENT THERAPY IN PULMONARY HYPERTENSION$192,910
M01 · FY2001 · RR
UT 15 IN PRIMARY PULMONARY HYPERTENSION PIVOTAL 12 WEEK STUDY$192,910
M01 · FY2001 · RR
SUBCUTANEOUS UT 15 IN PATIENTS W/ PRIMARY PULMONARY HYPERTENSION PRE$192,910
M01 · FY2001 · RR
SAFETY &EFFICACY OF TERBOGREL IN PATIENTS W/ PRIMARY PULMONARY HYPER$192,910
M01 · FY2001 · RR
NITRIC OXIDE IN PATIENTS WITH PULMONARY HYPERTENSION$192,910
M01 · FY2001 · RR
LONG TERM PROSTACYCLIN IN PULMONARY HYPERTENSION$192,910
M01 · FY2001 · RR
PROSTACYCLIN AND SUBSEQUENT THERAPY IN PULMONARY HYPERTENSION$0
M01 · FY2001 · RR
LONG TERM PROSTACYCLIN IN PULMONARY HYPERTENSION$0
M01 · FY2001 · RR
NITRIC OXIDE IN PATIENTS WITH PULMONARY HYPERTENSION$0
M01 · FY2001 · RR
SAFETY &EFFICACY OF TERBOGREL IN PATIENTS W/ PRIMARY PULMONARY HYPER$0
M01 · FY2001 · RR
SUBCUTANEOUS UT 15 IN PATIENTS W/ PRIMARY PULMONARY HYPERTENSION PRE$0
M01 · FY2001 · RR
UT 15 IN PRIMARY PULMONARY HYPERTENSION PIVOTAL 12 WEEK STUDY$0
M01 · FY2001 · RR
15AU81 SUB Q$121,168
M01 · FY2000 · RR
SURVEILLANCE OF PULMONARY HYPERTENSION IN AMERICA (SOPHIA)$121,168
M01 · FY2000 · RR
PROSTACYCLIN AND SUBSEQUENT THERAPY IN PULMONARY HYPERTENSION$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF TERBOGREL IN PATIENTS W/ PRIMARY PULMONARY HYPER$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF TERBOGREL IN PATIENTS W/ PRIMARY PULMONARY HYPER$0
M01 · FY2000 · RR
PROSTACYCLIN AND SUBSEQUENT THERAPY IN PULMONARY HYPERTENSION$0
M01 · FY2000 · RR
LONG TERM PROSTACYCLIN IN PULMONARY HYPERTENSION$0
M01 · FY2000 · RR
UT 15 IN PRIMARY PULMONARY HYPERTENSION PIVOTAL 12 WEEK STUDY$0
M01 · FY2000 · RR
UT 15 IN PRIMARY PULMONARY HYPERTENSION PIVOTAL 12 WEEK STUDY$0
M01 · FY2000 · RR
NITRIC OXIDE IN PATIENTS WITH PULMONARY HYPERTENSION$0
M01 · FY2000 · RR
LONG TERM PROSTACYCLIN IN PULMONARY HYPERTENSION$0
M01 · FY2000 · RR
SUBCUTANEOUS UT 15 IN PATIENTS W/ PRIMARY PULMONARY HYPERTENSION PRE$0
M01 · FY2000 · RR
SUBCUTANEOUS UT 15 IN PATIENTS W/ PRIMARY PULMONARY HYPERTENSION PRE$0
M01 · FY2000 · RR
NITRIC OXIDE IN PATIENTS WITH PULMONARY HYPERTENSION$0
M01 · FY2000 · RR